Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | +3.00% | -0.15% | -21.70% |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 109.8 | 144.5 | 116.4 | - | - |
Enterprise Value (EV) 1 | 109.8 | 144.5 | 116.4 | 116.4 | 116.4 |
P/E ratio | -4.97 x | -5.83 x | -4.91 x | -4.5 x | -4.06 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 59.1 x |
EV / Revenue | - | - | - | - | 59.1 x |
EV / EBITDA | -5.71 x | -6.31 x | -4.66 x | -3.96 x | -3.37 x |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 14,642 | 17,327 | 18,356 | - | - |
Reference price 2 | 7.500 | 8.340 | 6.340 | 6.340 | 6.340 |
Announcement Date | 3/8/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 1.971 |
EBITDA 1 | -12.89 | -19.23 | -22.9 | -25 | -29.4 | -34.5 |
EBIT 1 | -12.89 | -19.23 | -22.9 | -24.68 | -29.49 | -34 |
Operating Margin | - | - | - | - | - | -1,725.42% |
Earnings before Tax (EBT) 1 | -12.89 | -19.08 | -22.26 | -24.04 | -29.1 | -33.52 |
Net income 1 | -12.89 | -19.08 | -22.26 | -24.04 | -29.1 | -33.52 |
Net margin | - | - | - | - | - | -1,700.81% |
EPS 2 | -3.020 | -1.510 | -1.430 | -1.290 | -1.410 | -1.563 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/22/22 | 3/8/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -2.265 | -2.945 | -3.573 | -5.938 | -6.778 | - | -5.772 | -6.158 | -6.866 | -4.396 | -5.4 | -7.2 | -8 |
EBIT 1 | - | -2.945 | -3.573 | -5.938 | -6.778 | -4.101 | -5.772 | -6.158 | -6.866 | -4.396 | -6.005 | -6.216 | -6.492 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -2.261 | -2.943 | -3.569 | -5.877 | -6.696 | -4.049 | -5.708 | -5.881 | -6.622 | -4.171 | -5.694 | -6.426 | -6.825 |
Net income 1 | -2.261 | -2.943 | -3.569 | -5.877 | -6.696 | -4.049 | -5.708 | -5.881 | -6.622 | -4.171 | -5.694 | -6.426 | -6.825 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4800 | -0.3200 | -0.2800 | -0.4200 | -0.4800 | -0.2700 | -0.3800 | -0.3700 | -0.4100 | -0.2500 | -0.3067 | -0.3367 | -0.3433 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/22/22 | 5/12/22 | 8/10/22 | 11/8/22 | 3/8/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/5/24 | 5/7/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/22/22 | 3/8/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.70% | 116M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.47% | 16.37B | |
+2.23% | 13.58B | |
+27.13% | 11.66B |
- Stock Market
- Equities
- NVCT Stock
- Financials Nuvectis Pharma, Inc.